Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte

  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités

2 results

  • Active substance : doxazosine
Filter
Topic
  • Diseases and conditions (2)
  • Plus ...
    • Genital diseases (2)
    • Plus ...
      • Male genital diseases (2)
    • Urologic diseases (1)
    • Plus ...
      • Urination disorders (1)
  • Economics and public health (1)
  • Plus ...
    • Health economics (1)
  • Diagnostic and therapeutic techniques (1)
  • Plus ...
    • Surgical procedures (1)
    • Plus ...
      • Urogenital surgery (1)
Content type
  • Drugs, devices and medical acts (1)
  • Plus ...
    • Health technology assessment (1)
  • Practice Guidelines and Other Guides (1)
  • Plus ...
    • Practice guidelines (1)
Manufacturer
  • inconnu (2)
  • industriels (1)
Language
  • Français (2)
Active substance
  • aluminium (1)
  • aspirine (1)
  • clopidogrel (1)
  • doxazosine (2)
  • lithium (1)
  • mannitol (1)
  • phosphate (1)
  • potassium (1)
  • silodosine (1)
  • tamsulosine (2)
 More filter Other Filter Icon
Search Export

Practice guidelines and other guides - 1 result

  • Diagnosis and treatment of benign prostatic hyperplasia

    Practice guidelines - Posted on 1/3/2003 - Mis à jour le 19/7/2006
    Download abstract
    Add to my selection

Drugs, devices and medical acts - 1 result

  • Laser treatment of lower urinary tract symptoms associated with benign prostatic

    Health technology assessment - Posted on 12/12/2013
    Add to my selection

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
CWkLLFyw6mWQRF8h